CAP remains a major cause of morbidity and mortality. Advances in vaccination and diagnosis
should help reduce the amount of disease due to S. pneumoniae, the commonest cause …

Background A standardised approach to assessing COVID-19 survivors has not been
established, largely due to the paucity of data on medium- and long-term sequelae. Interval chest …

Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety and …

The response to the coronavirus disease 2019 (COVID-19) pandemic has been hampered
by lack of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

1 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus
in Wuhan, China. Lancet 2020; 395: 497–506. 2 Yin Y, Wunderink RG. MERS, SARS …

Opportunistic infections are a major cause of morbidity and mortality in severely
immunocompromised patients, such as those given chemotherapy or biological therapies, and those …

Streptococcus pneumoniae infections induce inflammatory responses that contribute toward
both disease pathogenesis and immunity, but the host–pathogen interactions that mediate …

Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare products
Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces lethal error …

Despite vaccines, Streptococcus pneumoniae kills more than a million people yearly. Thus,
understanding how pneumococci transition from commensals to pathogens is particularly …

Background The Covid-19 pandemic in the United Kingdom has seen two waves; the first
starting in March 2020 and the second in late October 2020. It is not known whether outcomes …